{"name":"Harrow","slug":"harrow","ticker":"HROW","exchange":"NASDAQ","domain":"harrow.com","description":"Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patien","hq":"Nashville, TN","founded":0,"employees":"373","ceo":"Mark L. Baum","sector":"Ophthalmology / Specialty Pharma","stockPrice":36.27,"stockChange":0.84,"stockChangePercent":2.37,"marketCap":"$1.4B","metrics":{"revenue":272303000,"revenueGrowth":33.3,"grossMargin":75.1,"rdSpend":20940000,"netIncome":-5139000,"cash":75055000,"dividendYield":0,"peRatio":13.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"1978-01-01","label":"Natacyn first approved","drug":"Natacyn","drugSlug":"natamycin","type":"approval","sentiment":"positive"},{"date":"1986-01-01","label":"Flarex first approved","drug":"Flarex","drugSlug":"fluorometholone-acetate","type":"approval","sentiment":"positive"},{"date":"1987-01-01","label":"Iopidine first approved","drug":"Iopidine","drugSlug":"apraclonidine","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Nevanac first approved","drug":"Nevanac","drugSlug":"nepafenac","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-12-01","label":"Nevanac patent expiry (Formulation)","drug":"Nevanac","drugSlug":"nepafenac","type":"patent_expiry","sentiment":"negative"},{"date":"2032-03-31","label":"Nevanac patent expiry (Formulation)","drug":"Nevanac","drugSlug":"nepafenac","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Vyzulta patent cliff ($143.8M at risk)","drug":"Vyzulta","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Xiidra patent cliff ($143.8M at risk)","drug":"Xiidra","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"NEPA","genericName":"NEPA","slug":"nepa","indication":"Post-Op Ocular Inflammation","status":"marketed"},{"name":"Nevanac","genericName":"NEPAFENAC","slug":"nepafenac","indication":"Post-Op Ocular Inflammation","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Iopidine","genericName":"APRACLONIDINE","slug":"apraclonidine","indication":"Cerebrovascular Occlusion","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Flarex","genericName":"FLUOROMETHOLONE ACETATE","slug":"fluorometholone-acetate","indication":"Steroid-responsive inflammatory conditions of the eye","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Natacyn","genericName":"NATAMYCIN","slug":"natamycin","indication":"Fungal Blepharitis","status":"marketed"}]}],"pipeline":[{"name":"Iopidine","genericName":"APRACLONIDINE","slug":"apraclonidine","phase":"marketed","mechanism":"Alpha-2A adrenergic receptor","indications":["Cerebrovascular Occlusion","Increased Intraocular Pressure after Ocular Procedure","Open-angle glaucoma","Percutaneous coronary intervention","Prevention of Cerebral Thrombosis"],"catalyst":""},{"name":"NEPA","genericName":"NEPA","slug":"nepa","phase":"marketed","mechanism":"Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase","indications":["Post-Op Ocular Inflammation","Postoperative Ocular Pain"],"catalyst":""},{"name":"Flarex","genericName":"FLUOROMETHOLONE ACETATE","slug":"fluorometholone-acetate","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":["Steroid-responsive inflammatory conditions of the eye"],"catalyst":""},{"name":"Natacyn","genericName":"NATAMYCIN","slug":"natamycin","phase":"marketed","mechanism":"Small molecule","indications":["Fungal Blepharitis","Fungal conjunctivitis","Fungal keratitis"],"catalyst":""},{"name":"Nevanac","genericName":"NEPAFENAC","slug":"nepafenac","phase":"marketed","mechanism":"Nevanac works by inhibiting the enzyme prostaglandin G/H synthase 2, which is involved in producing prostaglandins that cause pain and inflammation.","indications":["Post-Op Ocular Inflammation","Postoperative Ocular Pain"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Harrow Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Harrow reported fourth quarter and full year 2023 financial results, with revenue of $123.4 million and a net loss of $21.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Harrow Announces Partnership with Leading Eye Care Provider","summary":"Harrow announced a partnership with a leading eye care provider to expand access to its ophthalmology treatments.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-03","type":"pipeline","source":"simplywall.st","summary":"Is It Time To Reassess Harrow (HROW) After A 29.3% Year To Date Decline? - simplywall.st","headline":"Is It Time To Reassess Harrow (HROW) After A 29.3% Year To Date Decline?","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNWXRSM1lURzZaUV9xYXRlbzlUY2RpM1BVN2R1VGFHQmM3N3ZPQXRXYlhuOXpGOUhxczlySHFTYmpkVy12QnpHRV9WRlVZZzN3NEhKaFNnQWk4T0FDbTFzMnVDcmdlX2hoVHdVUDNEX25kYnRIMXI5QWRmSTVaLTNHNm1oZERWOEUwcGdCNEtmNmJvVFJDX2lfb3RZUWMzX2h0WC1WekR0MHNmNUloU19KaDZObnZyWUFD?oc=5","date":"2026-03-04","type":"pipeline","source":"Trefis","summary":"Harrow (HROW) -28%: 2026 Guidance Disappoints Market - Trefis","headline":"Harrow (HROW) -28%: 2026 Guidance Disappoints Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxQc0pqc3o2dlloY1JMcTJHZEFJMHNGZFUzODNtTWVPUUZ4ckdMY1pQZFJHTzBEZmNfenkxSEZTaFVTMzVmQXlleW1UQWNVb2VFQ1BGSWR4S19OY1ptWUlSdG1mcDM3amxDRWRRcnlRck5yY0hsYW5Kc0pIUjlkSHdsbVJocDR4T3VYR0MzUzFxTkJiVGNPTHVTaVJURF92UGh1UmFlUkpqckxZem95NGRJV3c1SEIxQWs5X2hqSHF5QjdBVnJQVDVkaTlGS3RLYXpXcXlLUzNrTENXR2xUQmUwY1gxMndua1pDU1NQcmdYX3pET25WaFRoampZcVRxMGpUdmJYbHVmSWUyaW5LUWFJ?oc=5","date":"2026-03-03","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Harrow Health (HROW) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Harrow Health (HROW)","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQcXBnT3lSVkZva19NelpKdEV6UEdQekg4N2hNeG03ODhHSEF0T2s5NmtFRDFjT040eGRlQllOVVRmRHFqNmJtS0c1QjYyOHJsVE1qdTMwVUk1OUQ5VEJyaWdyRjlfeHRTWTBIS1RMNGI0TmYxeXZFNGl1dnJUbTFBXzFjbnF5NTjSAY8BQVVfeXFMTUNzc3BLbXNXQ1hDWWlwZkxzbk9UcEZ5MjFSOXBGbkZzcWhTbklDTGpFV0p0dWh3VXo0SmVObHl2ZVQ5NUg1SFc4Y1ZLUTRTMUtGTURZSllIY3JJZWRvM3puaEIzdlVrTjQ3WVQtZHFSUklFRjFQd1lBQkdDOC14cEVGSXYxNmpxZmUwWjdmbXc?oc=5","date":"2026-01-15","type":"pipeline","source":"Insider Monkey","summary":"Harrow, Inc. (HROW): A Bull Case Theory - Insider Monkey","headline":"Harrow, Inc. (HROW): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQTkJXZ0xmQmYzc01qeU9LSmotd3ZwcVRIQkg2ZW9kWWJnRkZFcWtqMktmOVA2Rk5EV05RdG1faExJWEZHaVBNOXRuaE1FNVBiRTRocWx0OHAtd3JKNXFlV0FNWWRRakRrRnk4QnBZVFZ5UHExbms2N2lfRkRBQm9HMFVtX05IMTdIUmMzS1RTdDlKb1BQR2hkdDhma0s?oc=5","date":"2025-12-01","type":"pipeline","source":"Seeking Alpha","summary":"Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS (NASDAQ:HROW) - Seeking Alpha","headline":"Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS (NASDAQ:HROW)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_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?oc=5","date":"2025-11-23","type":"pipeline","source":"MSN","summary":"William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating - MSN","headline":"William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOSjBhcnc5S2dQQUNuamE4OTc1RzRWZE1JdlM4N2M5dy02TFVfSnN5aHhCcExGdkR1Zkt4RHRkZktiNnAwVzRiYnhPMUVTczJlTFV2T1lSZ2FoTnJXY2FjUm90R2ZCLWRFQXExNFlhbU9fNE93cVpRZDY1RC1xUU9nUmozNGhOQkEtZFEzcl9TNmNTWndRendZdjd0Sl9LLVNpVm9kWA?oc=5","date":"2025-11-18","type":"deal","source":"Stock Titan","summary":"Harrow (Nasdaq: HROW) Closes Melt Deal, Sets MELT-300 NDA Filing for 2027 in U.S. - Stock Titan","headline":"Harrow (Nasdaq: HROW) Closes Melt Deal, Sets MELT-300 NDA Filing for 2027 in U.S.","sentiment":"neutral"},{"date":"2025-11-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"Vyzulta","drugSlug":"latanoprostene-bunod","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":143800000},{"drugName":"Xiidra","drugSlug":"lifitegrast","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":143800000},{"drugName":"Nevanac","drugSlug":"nepafenac","patentNumber":"9662398","type":"Formulation","expiryDate":"2030-12-01","territory":"US","genericFilings":[]},{"drugName":"Nevanac","drugSlug":"nepafenac","patentNumber":"8921337","type":"Formulation","expiryDate":"2032-03-31","territory":"US","genericFilings":[]}],"drugCount":5,"phaseCounts":{"marketed":5},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Regeneron Pharmaceuticals (REGN)","Alcon (ALC)","Bausch Health (BHC)"],"therapeuticFocus":["Ophthalmology"],"financials":{"source":"sec_edgar+yahoo","revenue":272303000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":272303000,"period":"2025-12-31"},{"value":199614000,"period":"2024-12-31"},{"value":199614000,"period":"2024-12-31"},{"value":130193000,"period":"2023-12-31"},{"value":130193000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":20940000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-5139000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":399482000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":373,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":36.27,"previousClose":35.43,"fiftyTwoWeekHigh":54.85,"fiftyTwoWeekLow":20.85,"fiftyTwoWeekRange":"20.85 - 54.85","fiftyDayAverage":42.01,"twoHundredDayAverage":40.67,"beta":0.31,"enterpriseValue":1495614464,"forwardPE":13.3,"priceToBook":25.74,"priceToSales":4.96,"enterpriseToRevenue":5.49,"enterpriseToEbitda":30.64,"pegRatio":0,"ebitda":48821000,"ebitdaMargin":17.9,"freeCashflow":45183376,"operatingCashflow":43864000,"totalDebt":251976000,"debtToEquity":483.7,"currentRatio":2.2,"returnOnAssets":4.8,"returnOnEquity":-8.5,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":8,"targetMeanPrice":69.38,"targetHighPrice":91,"targetLowPrice":59,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":16.1,"institutionHeldPercent":60.6,"sharesOutstanding":37229705,"floatShares":27353409,"sharesShort":6245393,"shortRatio":5.86,"shortPercentOfFloat":16.8,"epsTrailing":-0.14,"epsForward":2.72,"revenuePerShare":7.41,"bookValue":1.41,"officers":[{"age":53,"name":"Mr. Mark L. Baum J.D.","title":"CEO, Chairman of the Board & Founder"},{"age":43,"name":"Mr. Andrew R. Boll C.F.A., C.M.A.","title":"President, CFO & Corporate Secretary"},{"age":53,"name":"Mr. Randall E. Pollard","title":"Chief Accounting Officer"},{"age":null,"name":"Dr. Amir W. Shojaei Ph.D., Pharm.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Mr. Michael D. Biega","title":"Vice President of Investor Relations & Communications"},{"age":null,"name":"Mr. Brett A. Burrell","title":"Vice President of Legal & Compliance"},{"age":null,"name":"Ms. Kim  Barratt","title":"Chief Talent Officer"},{"age":null,"name":"Dr. Mark A. Mannebach Ph.D., R.Ph.","title":"Head of Regulatory Affairs & Pharmacovigilance"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.harrow.com","phone":"615 733 4730"}}